Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse
Europace · 05.10.2023 · 25 (10)
DOI: 10.1093/europace/euad309 ↗Kurz gefasst
Kommentar in der Zeitschrift Europace, online erschienen am 18.10.2023. Verfasst von Christian K Five und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, ProCardio Center for Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway. Hauptthemen laut MEDLINE: Mitral Valve Prolapse, Tachycardia, Ventricular, Heart Arrest. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Norwegian Research council, ProCardio, GENE POSITIVE, EMPATHY.
Abstract (Originalsprache)
Aims
Patients with mitral valve prolapse (MVP) have high risk of life-threatening ventricular arrhythmias (VAs). Data on the impact of exercise on arrhythmic risk in these patients are lacking. We explored whether lifetime exercise dose was associated with severe VA and with established risk factors in patients with MVP. Furthermore, we explored the circumstances at the VA event. Methods and results In this retrospective cohort study, we included patients with MVP and assessed lifetime exercise dose as metabolic equivalents of task (MET) hours/week. Severe VA was defined as sustained ventricular tachycardia or fibrillation, aborted cardiac arrest, and appropriate shock by a primary preventive implantable cardioverter defibrillator. We included 136 MVP patients (48 years [interquartile range (IQR) 35–59], 61% female), and 17 (13%) had previous severe VA. The lifetime exercise dose did not differ in patients with and without severe VA (17 MET h/week [IQR 9–27] vs. 14 MET h/week [IQR 6–31], P = 0.34). Lifetime exercise dose > 9.6 MET h/week was a borderline significant marker for severe VA (OR 3.38, 95% CI 0.92–12.40, P = 0.07), while not when adjusted for age (OR 2.63, 95% CI 0.66–10.56, P = 0.17). Ventricular arrhythmia events occurred most frequently during wakeful rest (53%), followed by exercise (29%) and sleep (12%).
Conclusion
We found no clear association between moderate lifetime exercise dose and severe VA in patients with MVP. We cannot exclude an upper threshold for safe levels of exercise. Further studies are needed to explore exercise and risk of severe VA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, ProCardio Center for Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway.
- Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway.
ORCID-Profile: Christian K Five, Linda T Aaserud, Anna Isotta Castrini, Katarina Vlaisavljevic, Øyvind Lie, Christine Rootwelt-Norberg, Eivind W Aabel, Kristina H Haugaa
Förderung
- Norwegian Research council, ProCardio
- GENE POSITIVE
- EMPATHY
Zitieren
APA
Five, C. K., Hasselberg, N. E., Aaserud, L. T., Castrini, A. I., Vlaisavljevic, K., Lie, Ø., Rootwelt-Norberg, C., Aabel, E. W., & Haugaa, K. H. (2023). Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse. Europace, 25(10). https://doi.org/10.1093/europace/euad309
Vancouver
Five CK, Hasselberg NE, Aaserud LT, Castrini AI, Vlaisavljevic K, Lie Ø, et al. Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse. Europace. 2023;25(10). doi:10.1093/europace/euad309
BibTeX
@article{Five2023,
author = {Five, Christian K and Hasselberg, Nina E and Aaserud, Linda T and Castrini, Anna Isotta and Vlaisavljevic, Katarina and Lie, Øyvind and Rootwelt-Norberg, Christine and Aabel, Eivind W and Haugaa, Kristina H},
title = {Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse},
journal = {Europace},
year = {2023},
volume = {25},
number = {10},
doi = {10.1093/europace/euad309}
}
EUVIMED